Altimmune, Inc. (NASDAQ:ALT) is one of Goldman Sachs’ top penny stock picks. On June 26, the company reported positive topline results from its Phase 2b IMPACT trial evaluating Pemvidutide, a ...
Altimmune (NASDAQ:ALT) lost ~64% in the premarket on Thursday after the company announced a mixed readout from a mid-stage trial for pemvidutide, its experimental therapy for a liver condition known ...
Altimmune, Inc. (NASDAQ:ALT) fights for relevance in the arena of metabolic disease drug development, where pharma titans like Novo Nordisk (NVO) and Eli Lilly (LLY) battle for dominance over one of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback